DiscGenics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to IDCT for Degenerative Disc Disease
- Written by PR Newswire
 |
SALT LAKE CITY, Jan. 27, 2023 /PRNewswire/ --DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine...
